Zoetis/$ZTS
1D1W1MYTD1Y5YMAX
Capital at risk
About Zoetis
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
- Ticker
- $ZTS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 14,500
- Headquarters
- Parsippany, United States
- Website
- www.zoetis.com
Zoetis Metrics
BasicAdvanced
$30B
11.65
$6.13
0.73
$2.09
2.97%
Price and volume
Market cap
$30B
Beta
0.73
52-week high
$148.79
52-week low
$71.00
Average daily volume
5.3M
Dividend rate
$2.09
Financial strength
Current ratio
3.084
Quick ratio
1.575
Long term debt to equity
2.94
Total debt to equity
2.94
Dividend payout ratio (TTM)
33.71%
Interest coverage (TTM)
15.26%
Profitability
EBITDA (TTM)
4,067
Gross margin (TTM)
71.74%
Net profit margin (TTM)
27.69%
Operating margin (TTM)
38.11%
Effective tax rate (TTM)
20.07%
Revenue per employee (TTM)
$660,000
Management effectiveness
Return on assets (TTM)
15.36%
Return on equity (TTM)
64.91%
Valuation
Price to earnings (TTM)
11.649
Price to revenue (TTM)
3.225
Price to book
9.39
Price to tangible book (TTM)
-54.66
Price to free cash flow (TTM)
13.264
Free cash flow yield (TTM)
7.54%
Free cash flow per share (TTM)
5.383
Dividend yield (TTM)
2.93%
Forward dividend yield
2.97%
Growth
Revenue change (TTM)
1.58%
Earnings per share change (TTM)
6.23%
3-year revenue growth (CAGR)
5.03%
10-year revenue growth (CAGR)
6.96%
3-year earnings per share growth (CAGR)
8.90%
10-year earnings per share growth (CAGR)
16.92%
3-year dividend per share growth (CAGR)
13.74%
10-year dividend per share growth (CAGR)
19.19%
What the Analysts think about Zoetis
Analyst ratings (Buy, Hold, Sell) for Zoetis stock.
Analyst projections of the future price of Zoetis stock.
Bulls say / Bears say
Zoetis launched the long-acting osteoarthritis therapies Lenivia for dogs and Portela for cats in Canada and the EU, while securing additional European approvals; successful commercialization could create a new growth leg for its pain franchise. (news.zoetis.com) (Zoetis)
Livestock revenue grew 7% organically in Q2, and Zoetis gained multiple U.S. authorizations for Dectomax products addressing New World screwworm across cattle and other species, creating disease-response demand beyond its pressured U.S. pet business. (investor.zoetis.com) (Zoetis)
The VitalRADS acquisition expands Zoetis’ diagnostics platform with teleradiology, imaging and AI-assisted workflow capabilities, while management says its pipeline contains more than 12 potential blockbuster candidates across areas including kidney disease, oncology, cardiology, anxiety and obesity. (investor.zoetis.com) (Zoetis)
Zoetis cut its 2026 adjusted EPS outlook to $6.15–$6.25 from $6.85–$7.00 after Q2 revenue was flat and organic operational revenue declined 1%, indicating a sharp near-term earnings reset. (ca.marketscreener.com) (Reuters)
The U.S. segment declined 8% in Q1, with companion-animal revenue down 11% as price-sensitive owners reduced veterinary spending and competition intensified in dermatology and parasiticides. (marketscreener.com) (Reuters)
Key franchises face product-specific pressure: Q1 cited generic competition for Convenia and Cerenia, lower Librela sales, and heightened competition for Simparica Trio and dermatology products, making a rapid companion-animal recovery uncertain. (investor.zoetis.com) (Zoetis)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Zoetis Financial Performance
Revenues and expenses
Zoetis Earnings Performance
Company profitability
Upcoming events
No upcoming events
Zoetis News
AllArticlesVideos
Funds containing Zoetis
AllEURGBPUSD
Fund name | Fund size | $ZTS weighting |
|---|---|---|
VanEck Morningstar Wide Moat€GMVM | €407M | 1.83% |
VanEck Morningstar Wide Moat£MOGB | £354M | 1.83% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.78% |
Amundi S&P 500£500G | £6.6B | 0.55% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.50% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.